GFS Advisors LLC Purchases 1,999 Shares of Johnson & Johnson $JNJ

Key Points

• GFS Advisors LLC increased its holdings in Johnson & Johnson by 3.9%, acquiring an additional 1,999 shares, bringing their total to 53,338 shares valued at approximately $8.15 million.
• Johnson & Johnson reported a $2.26 EPS and $24.02 billion in revenue for the latest quarter, with analysts forecasting a 10.58 EPS for the year.
• The company recently announced a quarterly dividend of $1.30, translating to an annualized dividend yield of 2.7% and a payout ratio of 55.61%.

GFS Advisors LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.9% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 53,338 shares of the company's stock after purchasing an additional 1,999 shares during the quarter. GFS Advisors LLC's holdings in Johnson & Johnson were worth $8,147,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in JNJ. Vanguard Group Inc. boosted its holdings in Johnson & Johnson by 0.5% in the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company's stock worth $38,800,371,000 after acquiring an additional 1,170,120 shares in the last quarter. Northern Trust Corp boosted its holdings in Johnson & Johnson by 0.4% in the first quarter. Northern Trust Corp now owns 30,943,820 shares of the company's stock worth $5,131,723,000 after acquiring an additional 130,645 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after acquiring an additional 4,842,582 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Johnson & Johnson by 3.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company's stock worth $3,133,602,000 after acquiring an additional 712,181 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Johnson & Johnson by 2.5% in the first quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company's stock worth $3,031,955,000 after acquiring an additional 448,666 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Up 0.1%

Johnson & Johnson stock opened at $190.88 on Tuesday. The stock has a market cap of $459.71 billion, a PE ratio of 20.42, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a one year low of $140.68 and a one year high of $192.10. The stock has a fifty day moving average of $178.88 and a 200 day moving average of $163.97.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Wall Street Analysts Forecast Growth

Several research firms have commented on JNJ. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the company an "overweight" rating in a report on Friday, October 3rd. Sanford C. Bernstein upped their price target on Johnson & Johnson from $172.00 to $193.00 and gave the company a "market perform" rating in a report on Monday, October 6th. The Goldman Sachs Group upped their price target on Johnson & Johnson from $186.00 to $212.00 and gave the company a "buy" rating in a report on Thursday, October 9th. Finally, Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $192.94.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.